Management of Atrial Fibrillation in COVID-19 Pandemic.
Adrenergic beta-Antagonists
/ therapeutic use
Angiotensin-Converting Enzyme 2
Anti-Arrhythmia Agents
/ therapeutic use
Anticoagulants
/ therapeutic use
Antiviral Agents
/ therapeutic use
Atrial Fibrillation
/ drug therapy
Betacoronavirus
COVID-19
Catheter Ablation
/ methods
Coronavirus Infections
/ drug therapy
Cytokines
/ blood
Drug Interactions
Humans
Pandemics
Peptidyl-Dipeptidase A
/ metabolism
Pneumonia, Viral
/ drug therapy
Risk
SARS-CoV-2
COVID-19 Drug Treatment
Ablation
Antiarrhythmic drugs
Atrial fibrillation
Oral anticoagulation
Journal
Circulation journal : official journal of the Japanese Circulation Society
ISSN: 1347-4820
Titre abrégé: Circ J
Pays: Japan
ID NLM: 101137683
Informations de publication
Date de publication:
25 09 2020
25 09 2020
Historique:
pubmed:
11
9
2020
medline:
21
10
2020
entrez:
10
9
2020
Statut:
ppublish
Résumé
The health crisis due to coronavirus disease 2019 (COVID-19) has shocked the world, with more than 1 million infections and casualties. COVID-19 can present from mild illness to multi-organ involvement, but especially acute respiratory distress syndrome. Cardiac injury and arrhythmias, including atrial fibrillation (AF), are not uncommon in COVID-19. COVID-19 is highly contagious, and therapy against the virus remains premature and largely unknown, which makes the management of AF patients during the pandemic particularly challenging. We describe a possible pathophysiological link between COVID-19 and AF, and therapeutic considerations for AF patients during this pandemic.
Identifiants
pubmed: 32908073
doi: 10.1253/circj.CJ-20-0566
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Anti-Arrhythmia Agents
0
Anticoagulants
0
Antiviral Agents
0
Cytokines
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM